Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin vs Vancomycin/Linezolid in ABSSSI (DISCOVER 1)
NCT01339091Phase 3Completed
- Sponsor
- Allergan
- Start
- Mar 2011
- Primary completion
- Sep 2012
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of dalbavancin in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Allergan. Started Mar 2011; status: completed.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT01339091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01339091.